Royal Bank of Canada downgraded shares of Amneal Pharmaceuticals (NYSE:AMRX) from an outperform rating to a sector perform rating in a research report sent to investors on Thursday, BenzingaRatingsTable reports. They currently have $6.00 price objective on the stock, down from their previous price objective of $11.00.
Several other analysts also recently commented on AMRX. Cantor Fitzgerald reaffirmed an overweight rating and set a $130.00 target price (up previously from $116.00) on shares of Zoetis in a report on Wednesday, June 12th. Zacks Investment Research downgraded shares of ExlService from a hold rating to a sell rating in a report on Wednesday. Barclays reaffirmed a hold rating on shares of Bank of Montreal in a report on Tuesday, June 11th. ValuEngine downgraded shares of Whiting USA Trust II from a hold rating to a sell rating in a report on Tuesday, May 7th. Finally, Piper Jaffray Companies set a $92.00 target price on shares of Wintrust Financial and gave the stock a buy rating in a report on Monday, July 8th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $14.58.
Shares of AMRX stock opened at $3.70 on Thursday. The company has a market cap of $1.21 billion, a P/E ratio of 3.89, a price-to-earnings-growth ratio of 0.25 and a beta of 1.50. The company has a quick ratio of 1.37, a current ratio of 2.11 and a debt-to-equity ratio of 3.44. The business’s 50-day moving average is $7.12. Amneal Pharmaceuticals has a 52 week low of $3.69 and a 52 week high of $24.48.
Amneal Pharmaceuticals (NYSE:AMRX) last announced its earnings results on Thursday, May 9th. The company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.07). The company had revenue of $446.00 million for the quarter, compared to the consensus estimate of $438.18 million. Amneal Pharmaceuticals had a positive return on equity of 32.14% and a negative net margin of 3.75%. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. As a group, equities research analysts anticipate that Amneal Pharmaceuticals will post 0.91 earnings per share for the current fiscal year.
In other Amneal Pharmaceuticals news, SVP Pradeep Bhadauria acquired 7,000 shares of the company’s stock in a transaction on Wednesday, May 15th. The stock was acquired at an average price of $8.48 per share, for a total transaction of $59,360.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Joseph Todisco acquired 15,000 shares of the company’s stock in a transaction on Monday, May 13th. The stock was acquired at an average price of $9.88 per share, with a total value of $148,200.00. The disclosure for this purchase can be found here. Insiders acquired a total of 41,000 shares of company stock valued at $387,300 in the last quarter. Corporate insiders own 26.34% of the company’s stock.
A number of institutional investors have recently modified their holdings of AMRX. Bessemer Group Inc. acquired a new position in shares of Amneal Pharmaceuticals in the 4th quarter valued at approximately $34,000. Quantamental Technologies LLC raised its position in shares of Amneal Pharmaceuticals by 34.0% in the 1st quarter. Quantamental Technologies LLC now owns 6,700 shares of the company’s stock valued at $95,000 after buying an additional 1,700 shares in the last quarter. Meeder Asset Management Inc. raised its position in shares of Amneal Pharmaceuticals by 785.6% in the 1st quarter. Meeder Asset Management Inc. now owns 11,664 shares of the company’s stock valued at $166,000 after buying an additional 10,347 shares in the last quarter. First Mercantile Trust Co. raised its position in shares of Amneal Pharmaceuticals by 40.9% in the 1st quarter. First Mercantile Trust Co. now owns 11,932 shares of the company’s stock valued at $169,000 after buying an additional 3,461 shares in the last quarter. Finally, Amalgamated Bank acquired a new position in shares of Amneal Pharmaceuticals in the 4th quarter valued at approximately $174,000. Institutional investors and hedge funds own 36.05% of the company’s stock.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Featured Article: Stock Portfolio Tracker
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.